Q1 EPS Forecast for Beam Therapeutics Lowered by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of Beam Therapeutics in a note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.91) per share for the quarter, down from their previous estimate of ($0.88). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($3.74) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($1.99) EPS.

A number of other analysts also recently commented on BEAM. Royal Bank Of Canada increased their price objective on shares of Beam Therapeutics from $22.00 to $26.00 and gave the company a “sector perform” rating in a report on Wednesday, February 25th. Wedbush increased their price target on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. UBS Group began coverage on Beam Therapeutics in a research report on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. Tudor Pickering set a $41.00 target price on Beam Therapeutics in a report on Wednesday, January 21st. Finally, Evercore started coverage on Beam Therapeutics in a report on Monday, November 24th. They set an “outperform” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.19.

Beam Therapeutics Trading Down 7.0%

NASDAQ:BEAM opened at $25.52 on Thursday. The company has a market cap of $2.60 billion, a P/E ratio of -25.27 and a beta of 2.12. Beam Therapeutics has a twelve month low of $13.52 and a twelve month high of $36.44. The company’s 50-day moving average price is $28.87 and its 200-day moving average price is $25.40.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $3.46. The company had revenue of $114.11 million for the quarter, compared to analysts’ expectations of $13.22 million. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. The firm’s quarterly revenue was up 280.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.09) EPS.

Insider Activity

In related news, insider Christine Bellon sold 1,371 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $34.00, for a total value of $46,614.00. Following the sale, the insider directly owned 95,667 shares in the company, valued at approximately $3,252,678. The trade was a 1.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors have recently made changes to their positions in BEAM. CWM LLC raised its stake in Beam Therapeutics by 15.4% during the 4th quarter. CWM LLC now owns 2,466 shares of the company’s stock worth $68,000 after acquiring an additional 329 shares in the last quarter. Wealth Effects LLC grew its holdings in shares of Beam Therapeutics by 4.3% during the fourth quarter. Wealth Effects LLC now owns 9,600 shares of the company’s stock worth $266,000 after purchasing an additional 400 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Beam Therapeutics by 2.6% during the fourth quarter. Franklin Resources Inc. now owns 21,948 shares of the company’s stock worth $608,000 after purchasing an additional 566 shares during the last quarter. Arizona State Retirement System increased its position in shares of Beam Therapeutics by 2.2% during the third quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock worth $650,000 after purchasing an additional 580 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in shares of Beam Therapeutics by 48.7% in the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after purchasing an additional 707 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Recent quarterly results provide a fundamental offset: Beam reported a large upside in Q4 (strong revenue and EPS beat versus estimates), showing material revenue growth year-over-year which supports longer-term value.
• Neutral Sentiment: Beam disclosed a licensing/partnership restructuring after Japan’s Bio Palette exited the collaboration. The announcement is operationally significant but details on financial impact and timing are limited; investors are parsing implications for program timelines and rights. Article Title
• Neutral Sentiment: Recent short‑interest data in filings shows effectively zero reported short interest (likely a reporting/data anomaly). This makes short‑interest-driven squeezes or pressure unlikely based on the available data.
• Negative Sentiment: HC Wainwright cut multiple EPS forecasts on March 2, trimming Q1–Q4 2026 and pushing down FY2026–FY2029 (and into 2030) estimates — e.g., FY2026 to ($3.74) from ($3.53), FY2027 to ($3.60) from ($3.24), FY2028 to ($2.69) from ($2.11), and FY2029 to ($1.99) from ($1.66). Those downward revisions lower near‑term expectations for cash burn and profitability, putting selling pressure on the stock.
• Negative Sentiment: Technicals may amplify the move: the share price is trading below the 50‑day moving average (nearer the 200‑day), and BEAM’s elevated beta implies higher volatility on negative news.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.